Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Clinical trial NCT05360238 · TERMINATED

Trial details

NCT number: NCT05360238
Sponsor: Mustang Bio
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Follicular B-cell Non-Hodgkin's Lymphoma Mantle Cell Lymphoma Recurrent Mantle Cell Lymphoma Refractory Small Lymphocytic Lymphoma, Relapsed Waldenstrom's Macroglobulinemia Recurrent Waldenstrom's Macroglobulinemia Refractory Chronic Lymphoid Leukemia in Relapse B-cell Lymphoma Refractory

Start date: 2022-05-24
Primary completion: 2024-04-12
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.